Detailed Narrative
FY25 Financial Performance Highlights
Black Rose Industries reported a robust financial year 2025, with standalone revenue growing by 20% due to strong domestic sales. The company achieved its highest-ever turnover, marking a 21% increase from the previous financial year. This strong performance was complemented by improved EBITDA and PAT margins, attributed to effective cost efficiency initiatives and product-mix optimization. Consequently, EPS saw a growth of approximately 25% for the year.
Distribution Segment Drives Growth
The distribution segment was a primary growth driver in FY25, closing the year with an impressive 29% growth in value and 10% in volume. This segment continues to be a significant contributor, accounting for about 70% of the company's total top line. While domestic sales remained strong, merchant exports faced some challenges in Q4 due to uncertainties surrounding US tariff policies, though management expects improvement from Q2 FY26 onwards.
Manufacturing Business and Product Portfolio
In the manufacturing division, the company produces acrylamide liquid (32,000 MTPA capacity), polyacrylamide liquids (40,000 MTPA capacity, with new binder BRILBIND CE03 launched), acrylamide solid (3,600 MTPA capacity), and n-methylol acrylamide (NMA, 2,000 MTPA capacity). Acrylamide solid sales have increased manifold due to rationalized import pricing from China, and NMA serves as an import substitute. Margins in the manufacturing business dipped slightly during the year.
Raw Material Stability and Pricing Strategy
The price of acrylonitrile, a key raw material, remained range-bound between $1100-1350 during FY25, with a sudden dip observed in March. Despite this, the company maintained stable finished product realization and prices. Management emphasized its disciplined pricing strategy and focus on long-term customer relationships, aiming to be a reliable supplier amidst market volatility🌐.
Strategic Initiatives and New Projects
Black Rose Industries inaugurated a new R&D facility, which is expected to drive future innovations and new product development. The polyacrylamide solid project is progressing on schedule, with plant building already complete, and commercial production anticipated by the end of FY26 or early FY27. Additionally, a feasibility study is underway for an amine product manufacturing facility in collaboration with Koei Chemicals of Japan, a long-standing principal.
Capital Expenditure and Funding Outlook
The company has outlined a significant capex pipeline, with the polyacrylamide solid project estimated to cost between ₹60-100 crores. An additional ₹50 crores is earmarked for the amine project (subject to feasibility) and new land acquisition. Management stated that funding options, including internal accruals, debt, or fresh equity, are all open and a definitive call will be made once project modalities are finalized.
Market Diversification and Export Focus
Acknowledging the prolonged slowdown in the Morbi tile industry, a key market for polyacrylamide liquid, the company is proactively exploring alternative applications in sectors like textiles through R&D. Efforts are also being made to increase export business for acrylamide powder. Improved logistics and reduced freight costs are helping the company re-enter previously unviable export markets, contributing to diversified market outreach.